$IBRX with some more positive results for ANKTIVA. The actual cure for cancer that nobody is talk...
Twitter
Note: AI-generated summary based on third-party content. Not financial advice. Read more.
Quick Insights
ImmunityBio ($IBRX)'s ANKTIVA, combined with a checkpoint inhibitor, showed statistically significant immune restoration and improved overall survival in non-small cell lung cancer (NSCLC) patients, with responders experiencing a median overall survival of 16.2 months versus 11.8 months for non-responders. A Phase 3 trial (ResQ201A) is underway to confirm these benefits in second-line NSCLC. This suggests a potentially significant therapeutic advancement for $IBRX.
Ask about this postAnswers are grounded in this post's content.
Tweet
About Beanie
Beanie
By beaniemaxi
Crypto native since the early days. Went all in on DeFi summer. Then tripled down on NFTs. VC @gmcapital_. No paid promos. Not financial advice. I talk my book.